Protagonist Therapeutics Inc Stock Nasdaq
Stocks
US74366E1029
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - PTS | - |
|
| Market Cap | 9.39B 0 8.2B 7.71B 7.04B 13.21B 897B 13.21B 92.54B 35.71B 458B 35.25B 34.48B 1,477B | P/E 2026 * |
31.2x | P/E 2027 * | -306x |
|---|---|---|---|---|---|
| Enterprise Value | 8.85B 0 7.73B 7.27B 6.63B 12.45B 846B 12.45B 87.23B 33.66B 432B 33.23B 32.5B 1,393B | EV / Sales 2026 * |
16.3x | EV / Sales 2027 * | 43.6x |
| Free-Float |
97.68% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protagonist Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 69 | 01/12/2008 |
Asif Ali
DFI | Director of Finance/CFO | 52 | 18/04/2022 |
Venkat Thalladi
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 69 | 01/12/2008 |
Harold Selick
CHM | Chairman | 71 | 19/03/2014 |
William Waddill
BRD | Director/Board Member | 69 | 01/07/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.27% | +4.01% | +3.90% | +29.60% | 47.86B | |
| +0.75% | +0.96% | +45.56% | +34.10% | 44.46B | |
| -1.13% | +4.59% | +10.63% | +91.23% | 41.85B | |
| -0.25% | -2.11% | +333.86% | +550.14% | 41.34B | |
| -0.62% | -0.06% | +10.15% | +46.02% | 30.04B | |
| +0.22% | +2.54% | +27.40% | +158.32% | 17.59B | |
| -3.57% | -7.42% | - | - | 15.6B | |
| -3.37% | +2.14% | +22.20% | +39.39% | 15.69B | |
| -0.69% | +9.87% | -8.62% | - | 13.93B | |
| Average | -1.00% | +2.66% | +55.64% | +135.54% | 29.82B | |
| Weighted average by Cap. | -0.63% | +1.88% | +69.13% | +143.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 542M 0 474M 445M 406M 763M 51.84B 763M 5.35B 2.06B 26.47B 2.04B 1.99B 85.34B | 203M 0 178M 167M 152M 286M 19.45B 286M 2.01B 774M 9.93B 764M 747M 32.01B |
| Net income | 324M 0 283M 266M 243M 455M 30.95B 456M 3.19B 1.23B 15.81B 1.22B 1.19B 50.96B | -32.12M -0 -28.07M -26.38M -24.08M -45.19M -3.07B -45.2M -317M -122M -1.57B -121M -118M -5.06B |
| Net Debt | -538M -0 -470M -442M -403M -757M -51.46B -757M -5.31B -2.05B -26.28B -2.02B -1.98B -84.71B | -511M -0 -447M -420M -383M -719M -48.86B -719M -5.04B -1.94B -24.95B -1.92B -1.88B -80.44B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
